Study of LY4050784 for Advanced Solid Tumors with SMARCA4 Changes
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug, LY4050784, for people with advanced solid tumors that have a specific change in a gene called SMARCA4 (BRG1). The study aims to see if the drug is safe and effective. It may be an option for those who have tried other treatments or have no standard options left.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have an advanced solid tumor that has spread or cannot be removed, with a change in the SMARCA4 (BRG1) gene.
- You must have tried at least one standard treatment for your type of cancer, or there be no standard treatment available.
- You must have a performance status of 0 or 1, meaning you are up and active at least half of the day.
- In some parts of the study, your tumor must be measurable on scans; in other parts, it can be measurable or not.
- You cannot have certain other conditions, such as untreated brain tumors, serious heart issues, or a second active cancer within the last 2 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new drug called PLX-61639 for people with advanced solid tumors that have a specific SMARCA4 gene change. The drug aims to stop cancer growth by targeting the cells that lack this gene.
This trial tests a combination of a targeted drug (anlotinib) with chemotherapy for people with a specific type of lung cancer that has a genetic change called SMARCA4 deficiency. The goal is to see if this combination can shrink tumors and help people live longer without the cancer growing.
This trial tests a new combination of an immunotherapy drug (QL1706) with standard chemotherapy for people whose lung cancer has a specific genetic change (SMARCA4 deficiency). The goal is to see if this combination can shrink tumors and improve outcomes for this particular group of patients.
This trial studies a combination therapy (called ABCP) as the first treatment for advanced non-squamous lung cancer that has a specific genetic change called SMARCA4. The goal is to see if this treatment is safe and works well for people who have not had prior systemic therapy.
This trial tests a new drug (GS-5319) for adults with advanced solid tumors that have a specific genetic feature called MTAP deficiency. The drug may be given alone or with another treatment, and the goal is to see if it can shrink tumors or slow their growth.
This early-phase trial studies OMTX705, given by itself or with an anti–PD-1 immune therapy, in people with advanced solid cancers that can’t be cured or that stopped responding to standard treatments. It aims to check safety and see whether the treatment can shrink tumors or control disease.
Hear when a new Metastatic Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.